Skip to main content

Diagnostic innovations for critical care settings

Our innovative biomarkers address diagnostically underserved acute and critical care conditions such as acute kidney injury, sepsis, and acute heart failure. We work with internationally leading academic and non-academic medical centers as well as global IVD and pharma companies to bring these innovations closer to the patients.

Bridging science and patient care for acute challenges

Innovation

Our diagnostic innovations 

We address diagnostic blind spots by developing innovative biomarkers to support early intervention and personalized medicine in critical care.

Products

The products

We offer biomarker assays for research use and, through our licensing partners, make IVD products available for clinical diagnostics worldwide.

Collaborations

Biomarker outlicensing

For a broad market adoption of our first-in-class biomarkers, we partner with global IVD companies wishing to enrich their immunoassay portfolios.

 

Collaboration

Pharma collaborations

Our biomarkers can provide a solution for enrichment and increased efficacy strategies in critical care drug discovery to de-risk drug developments.

Latest News

01. July 2025
In a landmark study (1) published in Transplant International, led by Heidelberg University Hospital in Germany in collaboration with researchers from Sydney, Australia, Proenkephalin A 119-159 (penKid) is identified as a reliable biomarker for the early and precise assessment of graft function trajectories following kidney transplantation.
Read more
06. May 2025
Boditech Med Inc. and SphingoTec GmbHtoday announced the commercial launch of the AFIAS sphingotest® penKid® assay.
Read more
16. April 2025
Proenkephalin A 119–159 (penKid) has been successfully integrated into daily practice in intensive care unit (ICU), demonstrating its effectiveness in assessing kidney function and predicting acute kidney injury (AKI) in over 4,000 patients.
Read more

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Follow our Journey on Social Media